Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
159K
-
Shares change
-
+4.64K
-
Total reported value, excl. options
-
$515K
-
Value change
-
-$27.2K
-
Number of buys
-
1
-
Number of sells
-
-2
-
Price
-
$3.23
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q4 2023
5 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 159K shares
of 119M outstanding shares and own 0.13% of the company stock.
Largest 10 shareholders include JENNISON ASSOCIATES LLC (9.07M shares), Frazier Life Sciences Management, L.P. (8.76M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (8.47M shares), Rubric Capital Management LP (6.64M shares), Polar Capital Holdings Plc (6.3M shares), MORGAN STANLEY (6.08M shares), BlackRock Inc. (5.92M shares), VANGUARD GROUP INC (4.9M shares), FRANKLIN RESOURCES INC (4.66M shares), and Bain Capital Life Sciences Investors, LLC (3M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.